医疗专业人员

下面列出了当前开展的临床试验。

根据地点、状态和其他条件对此研究列表进行过滤。

1. (Apex) Bezuclastinib In Patients With Advanced Systemic Mastocytosis

   Scottsdale/Phoenix, Ariz.

   This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

2. Specialty Compared To Oncology Delivered Palliative Care For Treating Acute Myeloid Leukemia

   Rochester, Minn.

   The purpose of this study is to evaluate whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

3. Evaluating Intestinal Microbiome And Immune Function In Lymphoma

   Rochester, Minn.

   The purpose of this study is to examine the microbiome and immune function in patients with active lymphoma, and in patients with a history of lymphoma who are in clinical remission.

4. Epcoritamab Compared To Observation For Treating B-cell Lymphoma Patients Not In Complete Remission After CD19-directed CAR-T Therapy

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to compare epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. 

5. Testing The Addition Of An Anti-cancer Drug, ASTX727, To Chemotherapy (Paclitaxel) And Immunotherapy (Pembrolizumab) For Metastatic Triple-Negative Breast Cancer

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to test the safety, side effects, and best dose of ASTX727 when given together with paclitaxel and pembrolizumab in patients with triple-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). 

6. A Study Of The Health Issues Of Bleeding Disorders

   Rochester, Minn.

   The purpose of this study is to monitor and better understand the health issues of people with bleeding disorders.

7. Oncolytic Adenovirus Coding For TNFa And IL2 (TILT-123) With Pembrolizumab Or Pembrolizumab And Pegylated Liposomal Doxorubicin As Treatment For Ovarian Cancer. (PROTA)

   Rochester, Minn.

   The purpose of this study is to evaluate the safety [including dose-limiting toxicities (DLTs)] of the combination therapy of TILT-123 and pembrolizumab in patients with platinum resistant or refractory ovarian cancer.

8. A Registry Study For The Long-Term Outcomes Of Radiation Therapy

   Scottsdale/Phoenix, Ariz.

   The purpose of this long term registry study is to collect and analyze information from patients being treated with various forms of radiation therapy to improve the treatment of future patients.

9. Circulating Tumor Nucleic Acids To Monitor Treatment Response In Metastatic Melanoma Patients

   Scottsdale/Phoenix, Ariz.

   This project will investigate whether the analysis of nucleic acids circulating in the blood from tumors can allow real-time monitoring of treatment response to targeted therapy and immunotherapy for patients who have stage IV metastatic melanoma.

10. Testing The Addition Of MEDI4736 (Durvalumab) To Chemotherapy Before Surgery For Patients With High-Grade Upper Urinary Tract Cancer

    Rochester, Minn., Jacksonville, Fla.

    The purpose of this study is to compare the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.